Skip to main content Accessibility help
×
Home

What a difference a state makes: pharmaceutical innovation after the TRIPs agreement

  • Verena Schüren

Abstract

For more than a decade, political science scholars have stressed the harmonizing effect of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs). Recent implementation practices in developing countries, however, have challenged this view. In this article, I argue that different manifestations of innovation systems can lead to varying patterns of innovation. I substantiate this claim through a comparison between the pharmaceutical sectors of India and Brazil. Drawing on the NSI approach, my analysis reveals that different forms of state engagement have played a decisive role for the varying directions of post-TRIPs pharmaceutical innovation in the two countries. The article illustrates that developing countries can opt for different approaches to innovation even after TRIPs and that the socioeconomic effects of global IP regimes can only be assessed properly when taking into account the country-specific configurations of national innovation systems.

Copyright

Corresponding author

Center for International Political Economy, Otto Suhr Institute for Politcal Science, Free University Berlin, E-mail: verena.schueren@fu-berlin.de

References

Hide All
Abrol, D. 2006. “The Challenge of Transformation of Indian System(s) of Innovation.” In Proceedings of the Globelics India Conference (“Innovation Systems for Competitiveness and Shared Prosperity in Developing Countries”). Kerala, India.
Alger, J., Becerra-Posada, F., Kennedy, A., Martinell, E. and Cuervo, L. G. 2009. “National Health Research Systems in Latin America: A 14-Country Review.” Pan American Journal of Public Health 26: 447457.
Altenburg, T. 2009. “Building Inclusive Innovation Systems in Developing Countries: Challenges for IS Research.” In Handbook of Innovation Systems and Developing Countries, edited by Lundvall, B.-Å., Joseph, K. J. and Chaminade, C., 3356. Cheltenham & Northhampton, MA: Edward Elgar.
Amable, B. 2000. “Institutional Complementarity and Diversity of Social Systems of Innovation and Production.” Review of International Political Economy 7: 645687.
Barton, J., Alexander, D., Correa, C., Mashelkar, R., Samuels, G. and Thomas, S. 2002. Integrating Intellectual Property Rights and Development Policy (Report of the Commission on Intellectual Property Rights). London: Commission on Intellectual Property Rights.
Biehl, J. 2004. “The Activist State. Global Pharmaceuticals, Aids and Citizenship in Brazil.” Social Text 22: 105132.
Cassier, M. and Correa, M. 2007. “Intellectual Property and Public Health: Coping of HIV/Aids Drugs by Brazilian Public and Private Pharmaceutical Laboratories.” Electronic Journal of Communication, Information and Innovation in Health 1: 8390.
Chamas, C. I. 2005. “Developing Innovative Capacity in Brazil to Meet Health Needs.” MIHR Report to CIPH WHO ref. CIPH Study 10d (DGR): 75108.
Chataway, J., Tait, J. and Wield, D. 2007. “Frameworks for Pharmaceutical Innovation in Developing Countries – the Case of Indian Pharma.” Technology Analysis & Strategic Management 19: 697708.
Chaudhuri, S. 2007. “The Gap Between Successful Innovation and Access to Its Benefits: Indian Pharmaceuticals.” The European Journal of Development Research 19: 4965.
Chaudhuri, S. 2008. “Is Product Patent Protection Necessary to Spur Innovation in Developing Countries?.” In The Development Agenda, Global Intellectual Property and Developing Countries. Neil Weinstock.
Cohen, J. C. and Lybecker, K. M. 2005. “Aids Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health.” The World Economy 28: 211230.
Correa, C. M. 2011. “Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing.” South Centre Research Papers, No. 41.
Cozzens, S., Gatchair, S. and Thakur, D. 2006. “Distributional Assessment of Emerging Technologies. A Framework Analysis.” James Martin Institute Working Paper 1. Georgia Institute of Technology.
Cozzens, S. E. and Kaplinsky, R. 2009. “Innovation, Poverty and Inequality: Cause, Coincidence, or Co-Evolution?.” In Handbook of Innovation Systems and Developing Countries, edited by Lundvall, B.-A., Joseph, K. J., Chaminade, C. and Vang, J., 5782. Cheltenham and Northhampton: Edward Elgar.
Dahlman, C. 2010. “Innovation Strategies in Brazil, China and India: From Imitation to Deepening Technological Capability in the South.” In The Rise of Technological Power in the South, edited by Fu, X. and Soete, L., 1548. Houndsmills, Basingstoke, Hampshire: Palgrave Macmillan.
Damodaran, A. 2008. “Indian Patent Law in the Post-Trips Decade: S & T Policy Appraisal.” Journal of Intellectual Property Rights 13: 414423.
de Brito Cruz, C. H. and de Mello, L. 2006. “Boosting Innovation Performance in Brazil.” OECD Economics Department Working Papers from OECD Publishing, 532.
Deere, C. 2009. The Implementation Game: The TRIPs Agreement and the Global Politics of Intellectual Property Reform in Developing Countries. Oxford: Oxford University Press.
DIPP (Department of Industrial Policy & Promotion). 2010. Compulsory Licencing, Discussion Paper, April 17, 2013.
Doctor, M. 2009. Furthering Industrial Development in Brazil: Globalisation and the National Innovation System. Rio de Janeiro: Latin American Studies Association.
Drahos, P. 2004. “The Regulation of Public Goods.” Journal of International Economic Law 7: 321339.
Drahos, P. 2007. “Trust Me: Patent Offices in Developing Countries.” Australian National University Working Paper, 11.
Edquist, C. 2005. “Systems of Innovation – Perspectives and Challenges.” In Oxford Handbook of Innovation, edited by Fagerberg, J., Mowery, D. and Nelson, R., 181208. Oxford: Oxford University Press.
Eimer, T. and Lütz, S. 2010. “Developmental States, Civil Society, and Public Health: Patent Regulation for HIV/Aids Pharmaceuticals in India and Brazil.” Regulation and Governance 4: 135153.
Eimer, Thomas R., Lütz, S. and Schüren, V. 2013. “Norm Diffusion through Advocacy Coalitions: Implementing International Intellectual Property Norms in India and Brazil.” Paper presented at the ISA 54th Annual Convention, April, San Francisco.
Eren-Vural, I. 2007. “Domestic Contours of Global Regulation, Understanding the Policy Changes on Pharmaceutical Patents in India and Turkey.” Review of International Political Economy 14: 105142.
Ernst, D. 2002. “Global Production Networks and the Changing Geography of Innovation Systems: Implications for Developing Countries.” Economics of Innovation and New Technology 11: 497523.
Ferrer, M., Thorsteinsdóttir, H., Quach, U., Singer, P. A. and Daar, A. S. 2004. “The Scientific Muscle of Brazil's Health Biotechnology.” Nature Biotechnology 22: DC8DC12.
Floricel, S., Michela, J. and George, M. 2009. “Resource Feedbacks for Continuous Innovation: The Articulation of Firm, University, and Government Rules.” Paper to be presented at the CBS Summer Conference, 17–19 June 2009, Copenhagen.
Freeman, C. 1982. The Economics of Industrial Innovation. 2nd ed. Cambridge: MIT Press.
Flynn, M. 2008. “Public Production of Anti-Retroviral Medicines in Brazil, 1990–2007.” Development and Change 39: 513536.
Giugale, M. 2011, July 5. “Yes, They Can: How Emerging Economies Are Building Universal Health Coverage.” Accessed April 23, 2012. http://www.huffingtonpost.com/marcelo-giugale/developing-countries-universal-healthcare_b_1018240.html.
Gopakumar, K. M. 2010. “India: A Critical Review of the Implementation of Trips Patent Regime.” The Law and Development Review 3: 324368.
Federal, Governo. 2003. Diretrizes De Política Industrial, Tecnológica E De Comércio Exterior.
Guennif, S. and Ramani, S. V. 2012. “Explaining Divergence in Catching-up in Pharma between India and Brazil using the NSI-Framework.” Research Policy 41: 430441.
Halbert, D. J. 1999. Intellectual Property in the Information Age. The Politics of Expanding Ownership Rights. Westport, Connecticut: Quorum Books.
Hasenclever, L. and Paranhos, J. 2009. The Development of the Pharmaceutical Industry in Brazil and India: Technological Capability and Industrial Development. Mimeo.
Horner, R. 2013. “The Impact of Patents on Innovation, Technology Transfer and Health: A Pre- and Post-TRIPs Analysis of India's Pharmaceutical Industry.” New Political Economy 125. DOI:10.1080/13563467.2013.796446 [Epub Ahead of Print].
ICMR (Indian Council of Medical Research). 2008. Guidelines for Good Clinical Laboratory Practices (Gclp). New Delhi.
Interview 146 Representative of the Indian Ministry of Commerce and Industry. New Delhi, March 3, 2011.
Interview 154 Indian civil society representative. New Delhi, February 23, 2011.
Interview 156 Representative of an Indian pharmaceutical industry association. New Delhi, February 27, 2011.
Interview 166 Representative of the ENSP. Rio de Janeiro, July 25, 2011.
Interview 226 Representative of Fiocruz. Rio de Janeiro, August 31, 2011.
Interview 227 Representative of the Brazilian Ministry of Health. Brasília, August 11, 2011.
Interview 235 Representative of a Brazilian industry association. Sao Paulo, August 22, 2011.
Interview 236 Representative of Fiocruz, Rio de Janeiro, September 2, 2011.
Interview 245 Representative of the Brazilian Ministry of Health, CIS. Brasília, August 15, 2011.
Interview 246 Representative of the Brazilian Ministry of Foreign Affairs, Itamaraty. Brasília, August 6, 2011.
Interview 253 Representative of the Brazilian Ministry of Health. Brasília, August 5, 2011.
Interview 255 Representative of the Brazilian Ministry of Health. Brasília, August 10, 2011.
Interview 275 Representative of the Indian Council of Science & Industrial Research. New Delhi, February 7, 2012.
Interview 276 Former representative of the Indian Ministry of Commerce and Industry. New Delhi, February 8, 2012.
Interview 278 Representative of the Jawaharlal Nehru University, Centre for Studies in Science Policy. New Delhi, February 9, 2012.
Interview 279 Former representative of the Indian Ministry of Science and Technology. New Delhi, February 10, 2012.
Interview 280 Indian civil society representative, New Delhi, February 10, 2012.
Interview 283 Representative of the Indian Ministry of Health. New Delhi, February 13, 2012.
Interview 284 Representative of the Public Health Foundation of India. New Delhi, February 14, 2012.
Interview 295 Representative of the Pharmacy Council of India. New Delhi, February 15, 2012.
Interview 299 Representative of an Indian clinical research organization. New Delhi, February 17, 2012.
Interview 300 Representative of the Indian Council of Science & Industrial Research. New Delhi, February 21, 2012.
Interview 313 Representative of the Indian Council of Medical Research. New Delhi, February 23, 2012.
Interview 320 Representative of the Indian Ministry of Commerce and Industry. New Delhi, February 24, 2012.
Interview 322 Representative of the National Institute of Pharmaceutical Education and Research. Chandigarh, February 27, 2012.
Interview 324 Representative of the National Institute of Pharmaceutical Education and Research. Chandigarh, February 27, 2012.
Jeffrey, R. and Santhosh, M. 2009. “Architecture of Drug Regulation in India. What are the Barriers to Regulatory Reform?.” Journal of Health Studies 2: 1331.
Joshi, H. N. 2003. “Analysis of the Indian Pharmaceutical Industry: With Emphasis on Opportunities in 2005.” Pharmaceutical Technology 27: 7484.
Kapczynski, A. 2009. “Harmonization and Its Discontents: A Case Study of Trips Implementation in India's Pharmaceutical Sector.” California Law Review 97: 15711650.
Kaplan, W. and Laing, R., 2005. “Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines, an Overview of Key Concepts, Issues and Opportunities for Future Research.” Health, Nutrition and Population (HNP) Discussion Paper.
Krishna, V. V. 2001. “Changing Policy Cultures, Phases and Trends in Science and Technology in India.” Science and Public Policy 28: 179194.
Li, X. 2008. “The Impact of Higher Standards in Patent Protection for Pharmaceutical Industries under the TRIPs Agreement: A Comparative Study of China and India.” The World Economy 31: 13671382.
Love, J. P. 2007. “Recent Examples of the Use of Compulsory Licenses on Patents.” KEI Research Note, 2. Accessed April 27, 2012. http://www.keionline.org.
Lundvall, B.-Å. 1992. National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning. London: Pinter.
Lundvall, B.-Å. 2007. “National Innovation System. Analytical Concept and Development Tool.” Industry and Innovation 14: 95119.
Mahajan, M. 2011. “The Emergence of New R&D Paradigms in the Indian Pharmaceutical Industry: Post TRIPs Period.” Journal of Intellectual Property Rights 16 (July): 321329.
Malerba, F. 2005. “Sectoral Systems – How and Why Innovation differs across Sectors.” In The Oxford Handbook of Innovation, edited by Fagerberg, J., Mowery, D. C. and Nelson, R. R., 380406. Oxford: Oxford University Press.
Malerba, F. and Nelson, R. 2011. “Learning and Catching up in Different Sectoral Systems: Evidence from Six Industries.” Industrial and Corporate Change 20: 16451675.
Mani, S. 2006The Sectoral System of Innovation of Indian Pharmaceutical Industry.” Centre for Development Studies. Working Paper No. 382, 159.
May, C. 2000. A Global Political Economy of Intellectual Property Rights. The New Enclosures? London: Routledge.
May, C. and Sell, S. 2006. Intellectual Property Rights. A Critical History. London: Lynne Rienner Publishers.
Mkandawire, T. 2007. “Transformative Social Policy and Innovation in Developing Countries.” The European Journal of Development Research 19: 1329.
MoC&F (Ministry of Chemistry and Fertilizers). 2005. “National Pharmaceutical Policy.” Health Administrator XX: 18.
MoCI (Ministry of Commerce and Industry). 2008. Strategy for Increasing Exports of Pharmaceutical Products.
MS (Ministério da Saúde). 2011. “Acesso a Medicamentos Gratuitos Triplica No País.” Accessed September 13, 2011. http://portalsaude.saude.gov.br/portalsaude/index.cfm/?portal=pagina.visualizarNoticia&codConteudo=2309&codModuloArea=162&chamada=acesso-a-medicamentos-gratuitos-triplica-no-pais.
MST (Ministry of Science and Technology). 2003. Science and Technology Policy 2003.
Nair, M. 2008. “Compromizing Trips: Brazil's Approach to Tackle the HIV/Aids Imbroglio.” Journal of Intellectual Property Rights 13: 456463.
Nassif, A. 2007. “National Innovation System and Macroeconomic Policies: Brazil and India in Comparative Perspective.” Discussion Papers United Nations Conference on Trade and Development 184: 138.
Neeraj, S. S. 2011. “India Pharmaceutical-Industry as an Export Sector.” GITAM School of International Business. Accessed September 21, 2011. http://www.scribd.com/doc/48571412/Indian-Pharmaceutical-Export-Industry on April 12.
Nelson, R. R. 1992. National Innovation Systems: A Comparative Analysis. Oxford: Oxford University Press.
Niosi, J. 2011. “Building Innovation Systems: An Introduction to the Special Section.” Industrial and Corporate Change 20: 16371643.
OSEC. 2010Brazil's Pharmaceutical Industry.” Accessed March 22, 2012. http://www.osec.ch/de/blog/brazil%E2%80%99s-pharmaceutical-industry-opportunities-swiss-suppliers.
PAHO (Pan American Health Organization) and USAID. 2008. Brazil: Health Systems and Services Profile – Monitoring and Analysis of Health Systems Change/Reform, Brasilia, D.F., Brazil.
Paranhos, J. 2010. Interação Entre Empresas E Instituições De Ciência E Tecnologia No Sistema Farmacêutico De Inovação Brasileiro: Estrutura, Conteúdo E Dinâmica. Rio de Janeiro.
PCI (Pharmacy Council of India). 2010. “National Seminar on ‘Recent Trends in Pharmacy Education and Practice’.” Accessed March 20, 2012. http://pci.nic.in/PDF-Files/14-142%20%28Seminar%29.pdf.
Pharmainfo. 2008, March 13. “Pharm D. Program in India.” Pharmainfo.net. Accessed March 12, 2012. http://www.pharmainfo.net/abhi271183/pharmd-program-india.
Presidente da Républica. 2004. Lei De Inovação.
Rao, J. M. 2006. Globalization, Technology and Competition: Indian Pharmaceutical Industry in the Context of the WTO. Vidyanagar, Hyderabad: Media House Publications.
Rezaie, R., Daar, A., Maliakkal, M., Sammut, S., Frew, S. and Singer, P. 2008. “Brazilian Health Biotech – Fostering Crosstalk between Public and Private Sectors.” Nature Biotechnology 26: 627644.
Roemer-Mahler, A. 2013. “Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Protection of Intellectual Property Rights.” Review of International Political Economy 20: 121152.
Salama, B. and Benoliel, D. 2010. “Pharmaceutical Patent Bargains – the Brazilian Experience.” Cardozo Journal of International and Comparative Law 18: 633682.
Sampat, B. 2010. Institutional Innovation or Institutional Imitation? The Impact of Trips on India's Patent Law and Practice. New York: Columbia University.
Sampath, P. G. 2010. “Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry.” eSocialSciences Working Papers, 3336.
Schüren, V. 2012. “Two TRIPs to Innovation: Pharmaceutical Innovation Systems in India and Brazil.” SFB-Governance Working Paper Series, Berlin, Research Center 700.
Sell, S. K. 2003. Private Power, Public Law: The Globalization of Intellectual Property Rights. Cambridge: Cambridge University Press.
Shadlen, K. C. 2007. “The Political Economy of Aids Treatment: Intellectual Property and the Transformation of Generic Supply.” International Studies Quarterly 51: 559581.
Shadlen, K. C. 2009. “The Politics of Patents and Drugs in Brazil and Mexico: the Industrial Bases of Health Policies.” Comparative Politics 42: 4158.
Spicy, IP. 2012, May 12. “Parliamentary Standing Committee on Health Tables Damning Report on the Dangerous Liaisons between the DCGI & the Pharmaceutical Industry.” Accessed May 15, 2012. http://spicyipindia.blogspot.de/2012/05/parliamentary-standing-committee-on.html.
Thach, S. and Marsnik, S. J. 2009. “Patent Standards under Trips and the Pharmaceutical Industries in Brazil and India.” Latin American Business Review 10: 237261.
Thorsteinsdóttir, H., Quach, U., Martin, D. K., Daar, A. S. and Singer, P. A. 2004. “Introduction: Promoting Global Health through Biotechnology.” Nature Biotechnology 22: DC3DC7.
Thorsteinsdóttir, H., Quach, U., Daar, A. S. and Singer, P. A. 2004a. “Conclusions: Promoting Biotechnology Innovation in Developing Countries.” Nature Biotechnology 22: DC48DC7.
TOI (Times of India). 2012, February 13. “PMO Push for Free Drugs at Govt Hospitals.” Accessed April 16, 2012. http://articles.timesofindia.indiatimes.com/2012-02-13/india/31054648_1_health-care-medicines-drug-procurement.
Trans World News. 2011, January 6. “The Market for Pharmaceuticals in Brazil, Russia, India & China.” Accessed April 10, 2012. http://thegmd.transworldnews.com/NewsStory.aspx?id=747085&cat=0.
Tyfield, D. 2008. “Enabling TRIPs: The Pharma-Biotech-University Patent Coalition.” Review of International Political Economy 15: 535566.
Vieira, F. S. 2009. “Ministry of Health's depending on Drugs: Program Trends from 2002–2007.” Rev Saúde Pública 43: 206209.
Vieira, F. S. and Zucchi, P. 2011. “Resource Allocation for Pharmaceutical Procurement in the Brazilian Unified Health System.” Rev Saúde Pública 45: 906913.
Viotti, E. B. 2002. “National Learning Systems – a New Approach on Technological Change in Late Industrializing Economies and Evidences from the Cases of Brazil and South Korea.” Technological Forecasting & Social Change 69: 653–80.
Wade, R. 1990. Governing the Market: Economic Theory and the Role of Government in East Asian Industrialisation. Princeton: Princeton University Press.
WHO. 2004. The World Medicines Situation. Geneva: WHO.
WIPO. 2011a. Statistical Country Profiles – India. Geneva: WIPO.
WIPO. 2011b. Statistical Country Profiles – Brazil. Geneva: WIPO.
Wright, A. 2008. Innovation in Brazil: Public Policies and Business Strategies. Washington, D.C.: Woodrow Wilson Center for Scholars.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed